Asia Pacific Cell and Gene Therapy Market Size, Share, Trends, and Forecast to 2031

The Asia Pacific cell and gene therapy market is projected to reach US$ 8.98 billion by 2031 from US$ 1.51 bllion in 2024 at a CAGR of 29.1% during 2025–2031.

Asia Pacific Cell and Gene Therapy Market Analysis

The primary factors driving market growth include the increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing. Expansion of local manufacturing capabilities is expected to create ample opportunities for the Asia Pacific cell and gene therapy market in the coming years.

Asia Pacific Cell and Gene Therapy Market Overview

China, Japan, South Korea, India, and Australia are among the major investors in biomanufacturing, clinical trials, and the establishment of quality control laboratories. The countries are actively promoting the use of innovative technologies, including advanced gene editing, cell-sheet therapies, automation, and AI-enabled quality control. These advancements accelerate the development of therapies and enhance manufacturing stability. The need for treatments for cancer, rare diseases, and genetic disorders drives the demand for these therapies. Additionally, there is an increasing awareness and acceptance of regenerative and precision medicine approaches in the region.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Asia Pacific Cell and Gene Therapy Market: Strategic Insights

Asia Pacific Cell and Gene Therapy Market Drivers and Opportunities

Market Drivers:

• Rising Prevalence of Genetic Diseases: The increasing prevalence of inherited disorders is leading to the widespread use of carrier testing to inform reproductive decisions and reduce the risk of future health problems.
• Increasing Personalized/Preventive Healthcare Focus: The growth of personalized medicine and preventive care is a positive sign that patients and doctors will utilize carrier testing to identify genetic risks beforehand and plan for reproduction.
• Favorable Government & Regulatory Support: Encouraging policies, screening recommendations, and investments in genetic services are enabling more people to access carrier testing, whether due to the healthcare system's standardization or integration of routine healthcare.

Market Opportunities:

• Strategic Initiatives by Companies: Companies involved in the cell and gene therapy market focus on collaborations, expansions, agreements, partnerships, new launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance their capacity to cater to a large customer base.
• Expansion of Local Manufacturing Capabilities: The region is witnessing a transformative surge in CGT manufacturing, fueled by strategic investments and technology transfers that localize production and accelerate access to innovative treatments. This expansion addresses global supply chain vulnerabilities while fostering indigenous innovation, particularly in oncology and rare diseases.
• Rising Investments in R&D and Clinical Trials: The region is emerging as a powerhouse in CGT, fueled by robust investments in research and development and a proliferation of clinical trials.

Asia Pacific Cell and Gene Therapy Market Report Segmentation Analysis

The Asia Pacific cell and gene therapy market is segmented into various categories to provide a clearer understanding of its operations, growth potential, and current trends. Below is the standard segmentation approach used in industry reports:

By Type:

• Cell Therapy: Cell therapy demand is driven by substantial research investment, expanding manufacturing capacity, and increasing adoption of regenerative and oncology treatments across the region.
• Gene Therapy: Gene therapy advances are supported by improved regulations, rising clinical trial activity, and a growing focus on treating rare genetic and inherited diseases in the region.

By Service:

• Process​‍​‌‍​‍‌​‍​‌‍​‍‌ Development: Process development is about finding the most effective ways to scale up production that are of high quality and can be implemented in a factory to support the expanding clinical pipelines in the region and the commercialization of advanced therapies.
• cGMP Manufacturing: cGMP manufacturing involves producing cell and gene therapies in a compliant and reliable manner, supported by regional facilities that are growing, and the investment being made in a high-standard biomanufacturing infrastructure.
• Regulatory Services: Regulatory services are the means by which companies are guided through Asia Pacific approval routes by staff assisting in the preparation of documentation, ensuring compliance, and facilitating the rapid development of advanced therapeutic products.
• Bioassay Services: Bioassay services are the means by which analytical testing is conducted for potency, safety, and functionality, thereby ensuring consistent quality and regulatory compliance for cell and gene therapies produced locally.

By Scale:

• Pre-commercial/R and D Manufacturing: R&D manufacturing is a means of development that is supported by the early stages, and it involves small-batch production, which is flexible and rapid prototyping, and optimization of emerging therapies in the region is enabled.
• Commercial Scale Manufacturing: The emphasis in commercial manufacturing is on producing large-scale, compliant products that the expanding regional facilities support. Thus, a reliable supply can be maintained for approved therapies throughout APAC.

By Service Providers:

• CDMOs: CDMOs offer the integration of development and the provision of manufacturing support that results in a faster scale-up, alignment with regulations, and end-to-end services being available for regional therapy innovators.
• CMOs: CMOs provide the specialized manufacturing capacity that allows companies to release themselves from infrastructure burdens while meeting the rising demand for clinical and commercial-grade therapies in the region.

By Transfection Reagents:

• Polymer-based Transfection Reagents: Polymer-based reagents can support efficient gene delivery if the processes are scalable and cost-effective. Such methods are suitable for high-throughput research and early-stage therapy development.
• Lipid-based Transfection Reagents: Lipid-based reagents are an efficient way to deliver nucleic acids, and that is why they are heavily used in the development of therapeutics, since there is strong compatibility with cell and gene engineering.
• Viral Transduction Enhancers: The use of viral transduction enhancers results in the improvement of vector uptake and expression, which makes manufacturing more productive and consistent for complex cell and gene therapy workflows.
• Other Transfection Reagents: This category comprises the support given by the novel materials, emerging delivery tools, and enabling technologies to innovation and process efficiency throughout the therapy development ​‍​‌‍​‍‌​‍​‌‍​‍‌spectrum.

By End User:

• Contract Research Organizations
• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes

By Geography:

• Asia Pacific

Asia Pacific Cell and Gene Therapy Market Report Scope

Asia Pacific Cell and Gene Therapy Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Cell and Gene Therapy Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Asia Pacific Cell and Gene Therapy Market Share Analysis by Geography

The increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing drive the market growth.

Below is a summary of market share and trends by region:

1. Asia Pacific

• Market Share: Fastest-growing region with rising market shares every year
• Key Drivers: The adoption of cell and gene therapy is progressing rapidly due to continuous healthcare investment, growing awareness among the middle class, and increasing accessibility of genomic technologies.

• Trends: Improvements in access to genomics and increased consumer awareness

Asia Pacific Cell and Gene Therapy Market Players Density: Understanding Its Impact on Business Dynamics

High Market Density and Competition

Competition is intense due to established players such as WuXi AppTec Co Ltd and Lonza Group AG. Regional and niche providers, including CellVec Pte Ltd and Avance Clinical Pty Ltd, add to the competitive landscape across different regions.

This high level of competition urges companies to stand out by offering:

• Advanced products
• Value-added services such as customization and sustainable solutions
• Competitive pricing models
• Compliance with regulatory guidelines

Opportunities and Strategic Moves

• Companies are investing in research and development, driving innovation in detection technologies. These investments improve the sensitivity and specificity, addressing specific genetic health issues in different countries.
• Manufacturers will likely focus on local production to cut costs and strengthen supply chains, especially in high-volume markets such as India.

Other companies analyzed during the course of research:

1. OBiO Technology
2. Genepeutic Bio
3. Jubilant Biosys Ltd
4. Cyto‑Facto Inc.
5. BioCell Innovations Pte Ltd
6. Taiwan Cell Manufacturing Company (TCMC)
7. Aragen Life Sciences
8. Hetero Labs
9. BioXcellence
10. Catalent, Inc.

Asia Pacific Cell and Gene Therapy Market News and Recent Developments

• New Australian Collaboration to Advance Gene and Cell Therapy Sector: Viral Vector Manufacturing Facility (VVMF) and Cell Therapies co-signed a Memorandum of Understanding (MoU) to explore strategic collaboration opportunities aimed at strengthening the onshore development and manufacture of Advanced Therapy Medicinal Products (ATMPs).

Asia Pacific Cell and Gene Therapy Market Report Coverage and Deliverables

The "Asia Pacific cell and gene therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Asia Pacific cell and gene therapy market size and forecast at the regional and country levels for all the key market segments covered under the scope
• Asia Pacific cell and gene therapy market trends, and market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Asia Pacific cell and gene therapy market analysis covering key market trends, regional and country framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Asia Pacific cell and gene therapy market
• Detailed company profiles